Meeting Coverage

AAD

American Academy of Dermatology

At-Home Topical Therapy for Molluscum Contagiosum Gets High Marks

Almost 40% of patients had no more than one active lesion after 12 weeks of berdazimer gel

AAD over a photo of Ernest N. Morial Convention Center in New Orleans, Louisiana.

Latest AAD Meetings

Outlook for Itchy Prurigo Nodularis Continues to Improve With IL-31 Antagonist

Rapid reduction in itch, sleep disturbance, nodules after first dose of nemolizumab

March 22, 2023
Durable Vitiligo Responses With Topical Ruxolitinib

Responses often maintained after drug withdrawal, long-term persistence with ongoing treatment

March 21, 2023
High Rates of Psoriasis Clearance With Investigational TYK2 Inhibitor

Rates of 90% clearance approaching 50% at 12 weeks, with 100% clearance rates as high as 33%

March 21, 2023
Rapid Improvement in Atopic Dermatitis With Topical PDE4 Inhibitor

Disease status, itch improved significantly within 1 to 2 weeks with roflumilast cream

March 20, 2023
Response Rates in Hidradenitis Suppurativa Continue to Climb With New Therapies

New analyses show "unprecedented" rates of 50% to 100% improvement

March 20, 2023
Another Win for a JAK Inhibitor in Alopecia Areata

About 40% of patients go from nearly hairless to almost a full head of hair with deuruxolitinib

March 19, 2023
Biologic Switch Revs Up Response in Plaque Psoriasis

"Dramatic improvement" at 16 weeks with IL-23 blocker after lack of response to anti-IL-17 drug

March 19, 2023
Chronic Spontaneous Urticaria Responds Quickly to BTK Inhibitor

AAD data also promising for therapies in psoriasis, pyoderma gangrenosum

March 31, 2022
Psoriasis Therapy Has Mixed Effects on Cardiovascular Risk Factors

No reduction in vascular inflammation with apremilast but significant reduction in body fat

March 30, 2022
Significant Improvement in Vitiligo With JAK Inhibitor Therapy

Durable improvement in pigmentation with topical ruxolitinib, oral ritlecitinib

March 29, 2022
Atopic Dermatitis: Promising Data for New Mechanistic Approach

Rapid responses in a majority of patients in small trial of eblasakimab

March 28, 2022
Targeted Antibody Provides Significant Relief From Itchy Nodular Condition

Dupilumab reduces itch, lesion count in first phase III trial for prurigo nodularis

March 28, 2022
Dramatic, Durable Hair Growth With Oral JAK Inhibitor

Oral baricitinib superior to placebo at 36 weeks in BRAVE-AA1 and BRAVE-AA2 trials

March 27, 2022
Rapid Improvement in Atopic Dermatitis With New JAK1 Inhibitor

Plus: First-in-class drug shows promise in AD, BTK inhibitor active in pemphigus

May 3, 2021